Expanding the multipotent profile of huprine-tacrine heterodimers as disease-modifying anti-Alzheimer agents

Neurodegenerative Diseases

Volumn 10, Issue 1-4, 2012, Pages 96-99

  Muñoz Torrero, Diego ^a   Pera, Marta ^b   Relat, Júlia ^b   Ratia, Míriam ^b   Galdeano, Carles ^a   Viayna, Elisabet ^a   Sola, Irene ^a   Formosa, Xavier ^a   Camps, Pelayo ^a   Badia, Albert ^b   Clos, M Victòria ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT DE NEUROCIÈNCIES   (Spain)

Author keywords

Acetylcholinesterase inhibitor; Hydrogen peroxide insult; M 1 agonist; Neuroprotection

Indexed keywords

CHOLINESTERASE INHIBITOR; HUPRINE TACRINE HETERODIMER; HYDROGEN PEROXIDE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR; NEUROPROTECTIVE AGENT; PIRENZEPINE; QUINUCLIDINYL BENZILATE; TACRINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL CULTURE; CONTROLLED STUDY; DRUG BINDING; HIPPOCAMPUS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

AMINOQUINOLINES; ANALYSIS OF VARIANCE; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HIPPOCAMPUS; HUMANS; HYDROGEN PEROXIDE; MUSCARINIC ANTAGONISTS; NEUROBLASTOMA; OXIDATIVE STRESS; PIRENZEPINE; PROTEIN BINDING; PROTEIN MULTIMERIZATION; QUINUCLIDINYL BENZILATE; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TACRINE; TRITIUM;

EID: 84860216292     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000333225     Document Type: Article

References (17)

1. Van der Schyf CJ, Geldenhuys WJ, Youdim MBH: Multifunctional drugs: ladostigil, an anti-Alzheimer drug; in Martinez A (ed): Medicinal Chemistry of Alzheimer's Disease. Trivandrum, Transworld Research Network, 2008, pp 1-20.
2. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C: Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008; 51: 347-372.
3. Inestrosa NC, Alvarez A, Pérez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J: Acetylcholinesterase accelerates assembly of amyloid-3β -peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16: 881-891.
4. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH: Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258: 304-307.
5. Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olesen OF, Lovestone S: Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-33β inhibition and in neurons. J Neural Transm 2000; 107: 1201-1212.
6. Dorronsoro I, Castro A, Martínez A: Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease- modifying agents. Expert Opin Ther Pat 2003; 13: 1725-1732.
7. Caccamo A, Fisher A, LaFerla FM: M 1 agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr Alzheimer Res 2009; 6: 112-117.
8. Cavalli A, Bolognesi ML, Capsoni S, Andrisano V, Bartolini M, Margotti E, Cattaneo A, Recanatini M, Melchiorre C: A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Ed Engl 2007; 46: 3689-3692.
9. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM: M 1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006; 49: 671-682.
10. Fisher A: M1 muscarinic agonists target major hallmarks of Alzheimer's disease - The pivotal role of brain M 1 receptors. Neurodegener Dis 2008; 5: 237-240.
11. Fisher A: M 1 muscarinic agonists in the treatment of Alzheimer's disease; in Martinez A (ed): Medicinal Chemistry of Alzheimer's Disease. Trivandrum, Transworld Research Network, 2008, pp 111-133.
12. Muñoz-Torrero D, Camps P: Huprines for Alzheimer's disease drug development. Expert Opin Drug Discov 2008; 3: 65-81.
13. Alcalá MM, Maderuelo A, Vivas NM, Camps P, Muñoz-Torrero D, Clos MV, Badia A: Effects of ( 8 )-huprine Y and ( 8 )-huprine Z, two new anticholinesterasic drugs, on muscarinic receptors. Neurosci Lett 2005; 379: 106-109.
14. Hedberg MM, Clos MV, Ratia M, Gonzalez D, Unger Lithner C, Camps P, Muñoz-Torrero D, Badia A, Giménez-Llort L, Nordberg A: Effect of huprine X on3β 42-amyloid, synaptophysin and/α /e 7 neuronal nicotinic acetylcholine receptors in the brain of 3 ! Tg-AD and APPswe transgenic mice. Neurodegener Dis 2010; 7: 379-388.
15. Ratia M, Giménez-Llort L, Camps P, Muñoz- Torrero D, Clos MV, Badia A: Behavioural effects and regulation of PKC3β and MAPK by huprine X in middle aged mice. Pharmacol Biochem Behav 2010; 95: 485-493.
16. Camps P, Formosa X, Muñoz-Torrero D, Petrignet J, Badia A, Clos MV: Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors. J Med Chem 2005; 48: 1701-1704.
17. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.